T98G Xenograft Model Overview

The T98G xenograft model is derived from a human glioblastoma multiforme (GBM), one of the most aggressive forms of primary brain cancer. The T98G cell line was established from a 61-year-old male patient with recurrent glioblastoma and is characterized by rapid proliferation, resistance to DNA-damaging agents, and a mesenchymal-like phenotype. As a xenograft model, T98G offers robust tumorigenicity and is widely used for investigating therapeutic resistance, apoptosis evasion, and oncogenic signaling in treatment-refractory gliomas.

T98G tumors recapitulate critical features of human glioblastoma, including high mitotic activity, necrotic regions with pseudopalisading, and profound resistance to temozolomide (TMZ), the current chemotherapeutic standard of care for GBM. This model is particularly suitable for testing combination regimens targeting PI3K/AKT/mTOR, MAPK, and apoptotic signaling pathways, as well as agents that overcome resistance associated with DNA repair and cellular stress response mechanisms.

Request a Custom Quote for T98G Xenograft Model

Biological and Molecular Characteristics

The T98G cell line exhibits a complex and aggressive molecular phenotype. It harbors a mutant TP53 gene and shows overexpression of BCL-2, cyclin D1, and CDK4, contributing to cell cycle deregulation and resistance to apoptotic stimuli. Notably, T98G expresses high levels of MGMT (O6-methylguanine-DNA methyltransferase), which confers resistance to alkylating agents such as temozolomide by repairing DNA lesions induced by treatment.

EGFR expression is moderate, and although T98G lacks the EGFRvIII mutation commonly observed in some GBM subtypes, it does exhibit activation of downstream PI3K/AKT and ERK1/2 signaling pathways. The cell line also expresses markers of mesenchymal transition, including vimentin, fibronectin, and MMP-9, indicating invasive capacity and phenotypic plasticity.

Characteristic	T98G Profile
Tumor Type	Human glioblastoma multiforme (GBM)
TP53 Status	Mutant
MGMT Expression	High (confers TMZ resistance)
EGFR Expression	Moderate (EGFRvIII-negative)
PI3K/AKT Signaling	Active
MAPK/ERK Pathway	Active
Apoptosis Regulators	BCL-2+, Survivin+
Cell Cycle Markers	Cyclin D1+, CDK4+
Mesenchymal Markers	Vimentin+, Fibronectin+, MMP-9+
Invasiveness	High (in vitro and in vivo)

This resistance-prone, proliferative phenotype positions T98G as a critical model for testing experimental therapeutics in aggressive, treatment-refractory gliomas.

In Vivo Model Development and Tumorigenicity

T98G xenografts are typically generated in immunodeficient mice (e.g., nude, NOD/SCID, or NSG strains) using subcutaneous or orthotopic implantation methods. Subcutaneous tumors form in over 90% of mice when 5 × 10^6 to 1 × 10^7 cells are implanted with Matrigel, becoming palpable within 10–14 days and reaching 1,200–1,500 mm³ in 3–4 weeks.

Orthotopic (intracranial) models more accurately reflect human GBM biology, including diffuse infiltration, perivascular cuffing, and pseudopalisading necrosis. Although technically demanding, orthotopic T98G models are used for evaluating blood–brain barrier (BBB) permeability, CNS drug distribution, and radiation response. T98G is compatible with luciferase or fluorescent tagging for bioluminescence imaging and longitudinal tracking of tumor burden.

The model is ideal for short-to-intermediate duration therapy studies, and its aggressive growth kinetics allow clear differentiation between therapeutic response and resistance. It supports tumor volume monitoring, histological analysis, and pharmacokinetic/pharmacodynamic endpoint assessment.

Request a Custom Quote for T98G Xenograft Model

Histopathology and Immunohistochemical Profile

Histologically, T98G xenografts exhibit dense sheets of poorly differentiated glial-like cells with high nuclear-to-cytoplasmic ratios, nuclear pleomorphism, and brisk mitotic activity. Subcutaneous tumors show focal necrosis, while orthotopic tumors display classic features of GBM, including pseudopalisading necrosis, microvascular proliferation, and perivascular cell aggregation.

Immunohistochemical staining demonstrates high expression of Ki-67 (>70%), indicating a high proliferative index. Tumors are positive for vimentin, nestin, and glial fibrillary acidic protein (GFAP), confirming neural lineage with mesenchymal differentiation. MGMT expression is robust and cytoplasmic, consistent with TMZ resistance.

Staining for BCL-2, survivin, and phospho-AKT is positive throughout tumor sections, supporting a pro-survival, anti-apoptotic profile. MMP-9 is localized to invasive margins, and CD31 staining reveals moderate-to-high tumor vascularization, enabling adequate drug delivery in vivo.

Preclinical Applications and Drug Response

The T98G xenograft model is widely utilized for testing novel therapies targeting alkylating agent resistance, particularly in the context of high MGMT expression. It is resistant to temozolomide, making it an ideal platform for identifying synergistic or sensitizing agents that restore apoptotic response or inhibit DNA repair.

Due to its aggressive nature and mesenchymal phenotype, T98G is appropriate for preclinical evaluation of PI3K/AKT/mTOR inhibitors, MEK inhibitors, HDAC inhibitors, and BCL-2 family antagonists (e.g., ABT-263, venetoclax). The model has also been used in combination therapy studies involving radiation, checkpoint kinase inhibitors, and autophagy inhibitors to overcome survival adaptations.

In orthotopic applications, T98G supports studies of BBB-penetrant small molecules, nanoparticle drug delivery, and radiotherapy sensitizers. Its histological and molecular stability across passages makes it suitable for both exploratory and comparative therapeutic research in GBM.

Request This Model

To request the T98G xenograft model or integrate it into studies of temozolomide resistance, orthotopic glioblastoma therapy, or anti-apoptotic drug development, please use the quote request form below. Our team provides support for study planning, intracranial implantation, and CNS-targeted protocol design.

Request a Custom Quote for T98G Xenograft Model